NEW YORK (GenomeWeb News) — MDS today reported that fourth-quarter revenue for its Sciex division declined 5.5 percent to $69 million from $73 million year over year.
The company blamed the decline on currency effects but said organic revenues were up 1 percent.
MDS said Sciex’s organic increases came from growth in the small-molecule business and high-end triple quad and trap products, and from growth in India and China.
MDS did not break down R&D spending for the Sciex division but said that spending was down year over year because two products, the CellKey System and 4800 platforms have entered commercial production.
The company also did not break out earnings or a balance sheet for the unit.